Ritter pharmaceuticals reports q3 loss per share $0.23

Ritter pharmaceuticals reports financial results for the three and nine months ended september 30, 2019 and provides business update.q3 loss per share $0.23.net decrease in cash and cash equivalents in 2019 was due to our use of cash to fund the liberatus clinical trial.ritter pharmaceuticals- as of sept 30, co had cash,cash equivalents of about $2.0 million versus $14.8 million as of dec 31, 2018.
QLGN Ratings Summary
QLGN Quant Ranking